These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32434083)

  • 1. Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan.
    Feng JY; Huang WC; Lin SM; Wang TY; Lee SS; Shu CC; Pan SW; Chen CY; Lin CB; Wei YF; Tung CL; Li CP; Su WJ
    Int J Infect Dis; 2020 Jul; 96():550-557. PubMed ID: 32434083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.
    Noh CS; Kim HI; Choi H; Kim Y; Kim CH; Choi JH; Hyun IG; Baek MS
    Respir Med; 2019 Oct; 157():52-58. PubMed ID: 31522030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 5. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
    Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA
    BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of latent tuberculosis infection and treatment interruption in long-term care facilities: A retrospective cohort study in Taiwan.
    Chiu TF; Yen MY; Shie YH; Huang HL; Chen CC; Yen YF
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1310-1317. PubMed ID: 34686442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
    Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM; Nog R; Wu Y; Dhand A
    Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
    J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Getahun H; Matteelli A; Abubakar I; Aziz MA; Baddeley A; Barreira D; Den Boon S; Borroto Gutierrez SM; Bruchfeld J; Burhan E; Cavalcante S; Cedillos R; Chaisson R; Chee CB; Chesire L; Corbett E; Dara M; Denholm J; de Vries G; Falzon D; Ford N; Gale-Rowe M; Gilpin C; Girardi E; Go UY; Govindasamy D; D Grant A; Grzemska M; Harris R; Horsburgh CR; Ismayilov A; Jaramillo E; Kik S; Kranzer K; Lienhardt C; LoBue P; Lönnroth K; Marks G; Menzies D; Migliori GB; Mosca D; Mukadi YD; Mwinga A; Nelson L; Nishikiori N; Oordt-Speets A; Rangaka MX; Reis A; Rotz L; Sandgren A; Sañé Schepisi M; Schünemann HJ; Sharma SK; Sotgiu G; Stagg HR; Sterling TR; Tayeb T; Uplekar M; van der Werf MJ; Vandevelde W; van Kessel F; van't Hoog A; Varma JK; Vezhnina N; Voniatis C; Vonk Noordegraaf-Schouten M; Weil D; Weyer K; Wilkinson RJ; Yoshiyama T; Zellweger JP; Raviglione M
    Eur Respir J; 2015 Dec; 46(6):1563-76. PubMed ID: 26405286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
    Cui X; Gao L; Cao B
    Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study.
    Cao X; Guo T; Xin H; Du J; Yang C; Feng B; He Y; Shen L; Di Y; Li Z; Chen Y; Liang J; Jin Q; Wang L; Gao L
    Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):809-820. PubMed ID: 38383889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study on prevalence of latent tuberculosis infection and outcome of 3HP treatment in patients under hemodialysis in Taiwan.
    Wu CH; Su HA; Chou CA; Liu JW; Lee CT; Dai LH; Yang CC
    J Formos Med Assoc; 2021 Jun; 120(6):1350-1360. PubMed ID: 34074499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.
    Huang HL; Lee MR; Cheng MH; Lu PL; Huang CK; Sheu CC; Lai PC; Chen TC; Wang JY; Chong IW
    Clin Infect Dis; 2021 Sep; 73(5):e1064-e1071. PubMed ID: 33215187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study.
    Huang HL; Huang WC; Lin KD; Liu SS; Lee MR; Cheng MH; Chin CS; Lu PL; Sheu CC; Wang JY; Lee IT; Chong IW
    Clin Infect Dis; 2021 Sep; 73(6):e1252-e1260. PubMed ID: 33677558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.